While the combination of sCD40L and monocyte chemoattractant protein 1 (MCP1)/CCL2 could be used to distinguish RRMS from SPMS, elevated sCD40L and IFN-γ levels are best at differentiating SPMS from BMS [99]. The gene discussed is CCL2; the disease is secondary progressive multiple sclerosis.